Friday, Dec. 8

7:45 – 8 a.m.  Welcome and Introductions
Cathleen Gates
Chief Executive Officer, American College of Cardiology

B. Hadley Wilson, MD, FACC
President, American College of Cardiology

Srihari S. Naidu, MD, FACC
President, New York State Chapter of the American College of Cardiology

Cardiovascular and Coronary Artery Disease: Challenges in 2023

Session I: Evolving New Frontiers of Imaging Ready For Practice
Chair: B. Hadley Wilson, MD, FACC

8 – 8:25 a.m.  Evolving High Predictability by Age 20-50 Years of Later CV Events and Dementia: The CARDIA (Risk Frs), PESA and BIOIMAGE (Femoral and Carotid VUS) Studies
Valentin Fuster, MD, PhD, MACC

8:25 – 8:50 a.m.  Evolving Imaging Approaches For a Full Evaluation of Coronary Disease: CTA Anatomy, Plaque Structure and Functional Characteristics
Leslee J. Shaw, PhD, FACC

8:50 – 9:10 a.m.  Evolving Tools Interpreting and Targeting Vasomotion Dependent Ischemia Epicardial, Microvasculature and Takotsubo Syndromes
Viviany R. Taqueti, MD, MPH, FACC

9:10 – 9:35 a.m.  Panel Discussion
Valentin Fuster, MD, PhD, MACC; Leslee J. Shaw, PhD, FACC; and Viviany R. Taqueti, MD, MPH, FACC

9:35 – 9:50 a.m.  Break
Visit the Expo

Session II: Acute Coronary Syndrome and COVID Advances
Chair: TBD

*Agenda as of Oct. 20, 2023. Subject to change.*
9:50 – 10:15 a.m. STEMI and Non-STEMI Types 1 and 2: Evolving Answers to Ten Recent Critical Questions, Five of Each  
Deepak L. Bhatt, MD, MPH, FACC

10:15 – 10:40 a.m. Evolving Strategies of Antithrombotic Therapy in Four Stages of CAD, ACS, Post PCI 1, 6 and 12 Months, Chronic CAD, Post MI LV Dysfunction  
Dominick J. Angiolillo, MD, PhD, FACC

10:40 – 11 a.m. Evolved Subacute and Chronic Impact of COVID-19 on Cardiovascular Sequelae Autonomic Nervous System Dysfunction (ANSD) as a Primary Concern  
Tyler J. Gluckman, MD, FACC

11 – 11:30 a.m. Panel Discussion  
Deepak L. Bhatt, MD, MPH, FACC; Dominick J. Angiolillo, MD, PhD, FACC; and Tyler J. Gluckman, MD, FACC

11:30 a.m. – 1 p.m. Break  
Lunch and Visit the Expo

11:45 a.m. – 1 p.m. Sponsored Lunch Symposium

Session III: Chronic Coronary Disease, Stroke and Pulmonary Embolism  
Chair: Argy Hillis, MD

1 – 1:25 p.m. Evolution in the Management of Stable Coronary MVD, CABG, PCI, CABG vs PCI, OMT vs CABG/PCI  
Valentin Fuster, MD, PhD, MACC

1:25 – 1:50 p.m. Evolving Strategies For The Management of Cerebrovascular Disease, Carotid Disease, Ischemic Stroke and Hemorrhagic Stroke  
Elisabeth B. Marsh, MD

1:50 – 2:15 p.m. Evolving Advances in DVT and Pulmonary Emboli Evaluation, Prevention and Management  
Gregory Piazza, MD, MS, FACC

2:15 – 2:45 p.m. Panel Discussion  
Valentin Fuster, MD, PhD, MACC; Elisabeth B. Marsh, MD; and Gregory Piazza, MD, MS, FACC

2:45 – 3 p.m. Break

*Agenda as of Oct. 20, 2023. Subject to change.
Visit the Expo

Session IV: Trends and Challenges of Approaching Prevention – Health Factors
Chair: TBD

3 – 3:20 p.m.  
Cardiorespiratory Fitness: Peak O2 / MET’s - Survival Physical Activity as the Best Investment in Preventive CV Medicine  
Carl J. Lavie Jr., MD, FACC

3:20 – 3:40 p.m.  
Obesity as a Huge Epidemiological Challenge From Genetics and Behavior to New Pharmacotherapy and Bariatric Surgery  
Tiffany Powell-Wiley, MD, MPH

3:40 – 4 p.m.  
Lipid-Modifying Agents as a Continuous Success Development From Statins to PCSK9 Inhibitors/Inclisiran and ANGPTL3 Inhibitors  
Robert S. Rosenson, MD, FACC

4 – 4:20 p.m.  
Diabetic-Modifying Agents in Evolution From Metformin to SGLT2 Inhibitors, GLP1 Receptor Agonists and Beyond  
David Preiss, MD, PhD

4:20 – 4:40 p.m.  
Hypertension as Number One Killer of CVD Seems to Be Neglected: An Obsession on BP Levels But Not in Identifying and Following the Affected  
Franz H. Messerli, MD, FACC

4:40 – 5 p.m.  
Panel Discussion  
Carl J. Lavie Jr., MD, FACC; Tiffany Powell-Wiley, MD, MPH; Robert S. Rosenson, MD, FACC; David Preiss, MD, PhD; and Franz H. Messerli, MD, FACC

5 p.m.  
Adjournment

Saturday, Dec. 9

Cardio-Pulmonary and Electrical Failure 2023

Session V: Myocardial Disease and Heart Failure: Basis For Management
Chair: Maria R. Costanzo, MD, FACC

*Agenda as of Oct. 20, 2023. Subject to change.
8 – 8:20 a.m. Evolving Imaging Approaches (MRI, PET) For 7 Myocardial Diseases: Myocarditis, DCM, HCM, NCLV, Amyloid CM, Sarcoid and Takotsubo - Diagnostic and Prognostic Implications Marcelo F. Di Carli, MD

8:20 – 8:40 a.m. Evolving Clinical Genetics and Omics in Seven Myocardial Diseases: Which Subgroup or When Should Be Gene Tested Amy Kontorovich, MD, PhD, FACC

8:40 – 9 a.m. HFrEF vs HFiEF vs HFpEF Phenotypes: Evolving Role of Beta-blockers, ARNI, SGLT2i and MRAs in the Three Entities Maria R. Costanzo, MD, FACC

9 – 9:20 a.m. Heart Failure, Chronic Kidney Disease and Diabetes: Evolving Role of SGLT2i in the Three Entities, Independent or Combined Biykem Bozkurt, MD, PhD, FACC

9:20 – 9:40 a.m. Myocarditis, AL/TTR Amyloid and NCLV: Evolving Approaches to These Three Challenging Myocardial Diseases Mathew S. Maurer, MD, FACC

9:40 – 10 a.m. Assist Devices and/or Transplantation in Cardiac Decompensation: Evolving Use of LVADs vs Impella vs ECMO and/or Donor Developments Sean P. Pinney, MD, FACC

10 – 10:30 a.m. Panel Discussion Marcelo F. Di Carli, MD; Amy Kontorovich, MD, PhD, FACC; Maria R. Costanzo, MD, FACC; Biykem Bozkurt, MD, PhD, FACC; Mathew S. Maurer, MD, FACC; and Sean P. Pinney, MD, FACC

10:30 – 10:45 a.m. Break Visit the Expo

Session VI: Rhythm Disorders, Contemporary and Future Topics of Focus
Chair: Francis E. Marchlinski, MD, FACC

10:45 – 11:05 a.m. Atrial Fibrillation: Evolving Clinical Challenges, Quality of Life and Preventing Stroke — Last Year Developments Valentin Fuster, MD, PhD, MACC

11:05 – 11:20 a.m. Atrial Fibrillation: Evolving Ablation Tools and LAA Closure — Who, When, How and Long Term Results?

*Agenda as of Oct. 20, 2023. Subject to change.*
Vivek Y. Reddy, MD

11:20 – 11:35 a.m.  Vasovagal Syncope and POTS: Cardioneuroablation and Evolving Therapies
  Josef Kautzner, MD, PhD

11:35 – 11:50 a.m.  Ventricular Tachycardia: Catheter Ablation — Who, When, How and Long Term Results?
  Francis E. Marchlinski, MD, FACC

11:50 – 12:05 p.m.  Follow Up of Three Device Therapeutic Approaches: CRTs, Subcutaneous ICDs, Leadless Pacemakers — Who, When, How and Long Term Results?
  Jeanne E. Poole, MD, FACC

12:05 – 12:30 p.m.  Panel Discussion
  Valentin Fuster, MD, PhD, MACC; Vivek Y. Reddy, MD; Josef Kautzner, MD, PhD; Francis E. Marchlinski, MD, FACC; and Jeanne E. Poole, MD, FACC

12:30 – 2 p.m.  Break
  Lunch and Visit the Expo

12:45 – 2 p.m.  Sponsored Lunch Symposium

Valvular Heart Disease and Aorta: Challenges in 2023

Session VII: Management of Aortic Valve Disease and Aorta
Chair: Robert O. Bonow, MD, MACC

2 – 2:20 p.m.  The Ten Major Advances in Structural Heart Disease in 2022-2023
  Samin K. Sharma, MBBS, FACC

2:20 – 3 p.m.  Aortic Valvular Disease: Nine Diagnostic and Management Challenges

<table>
<thead>
<tr>
<th>Condition</th>
<th>Classification</th>
<th>Intervention Comparison</th>
</tr>
</thead>
<tbody>
<tr>
<td>Aortic Stenosis</td>
<td>Asymptomatic</td>
<td>TAVR vs SVAR</td>
</tr>
<tr>
<td>Aortic Stenosis</td>
<td>Congenital Bicuspid</td>
<td>TAVR vs SVAR</td>
</tr>
<tr>
<td>Aortic Stenosis</td>
<td>Low Surgical Risk</td>
<td>TAVR vs SVAR (ie Ross)</td>
</tr>
<tr>
<td>Aortic Stenosis</td>
<td>Significant CAD</td>
<td>TAVR vs SVAR</td>
</tr>
<tr>
<td>Aortic Stenosis</td>
<td>Associated Mitral R</td>
<td>TAVR vs SVAR</td>
</tr>
<tr>
<td>Aortic Stenosis</td>
<td>Low Flow/Low Gradient</td>
<td>TAVR vs SVAR</td>
</tr>
<tr>
<td>Aortic Insufficiency</td>
<td>Asymptomatic</td>
<td>When to Intervene</td>
</tr>
</tbody>
</table>

*Agenda as of Oct. 20, 2023. Subject to change.*
Aortic Insufficiency

Aortic Stenosis/
Aortic Insufficiency

Without Dilated Aorta
Both Moderate

TAVR vs SVAR
TAVR vs SAVR

Presenter: Martin B. Leon, MD, FACC
Discussants: David H. Adams, MD, FACC; Robert O. Bonow, MD, MACC; Ismail El-Hamamsy, MD, PhD; Rebecca T. Hahn, MD, FACC; Samin K. Sharma, MBBS, FACC; and Gregg W. Stone, MD, FACC

3 – 3:25 p.m.

The Dilated Thoracic and Abdominal Aorta: Evolving Understanding of the Basic Biology and Management
Presenter: Valentin Fuster, MD, PhD, MACC
Discussant: Ismail El-Hamamsy, MD, PhD

3:25 – 3:40 p.m.

Break
Visit the Expo

Session VIII: Management of Mitral Regurgitation, Tricuspid Regurgitation and Hypertrophic Cardiomyopathy
Chair: David H. Adams, MD, FACC

3:40 – 4:15 p.m.

Mitral Regurgitation: Five Diagnostic and Management Challenges

<table>
<thead>
<tr>
<th>Primary Mitral Regurgitation</th>
<th>Asymptomatic</th>
<th>When to Intervene?</th>
</tr>
</thead>
<tbody>
<tr>
<td>Primary Mitral Regurgitation</td>
<td>Significant, Age 30</td>
<td>EtE R vs SMVR</td>
</tr>
<tr>
<td>Primary Mitral Regurgitation</td>
<td>Significant, Age 60</td>
<td>EtE R vs TMVR vs SMVR</td>
</tr>
<tr>
<td>Secondary Mitral Regurgitation</td>
<td>Significant, EF/RF?</td>
<td>EtE R vs OMT Alone</td>
</tr>
<tr>
<td>Secondary Mitral Regurgitation</td>
<td>Significant, PH/TR?</td>
<td>EtE R vs OMT Alone</td>
</tr>
</tbody>
</table>

Presenter: Robert O. Bonow, MD, MACC
Discussants: David H. Adams, MD, FACC; Ismail El-Hamamsy, MD, PhD; Rebecca T. Hahn, MD, FACC; Martin B. Leon, MD, FACC; Samin K. Sharma, MBBS, FACC; and Gregg W. Stone, MD, FACC

4:15 – 4:35 p.m.

Tricuspid Regurgitation: Four Diagnostic and Management Challenges

*Agenda as of Oct. 20, 2023. Subject to change.*
### Tricuspid Regurgitation

<table>
<thead>
<tr>
<th>Tricuspid Regurgitation</th>
<th>Symptomatic or Not</th>
<th>When Consider Intervention?</th>
</tr>
</thead>
<tbody>
<tr>
<td>Primary Without PH</td>
<td>TEER vs STVR</td>
<td></td>
</tr>
<tr>
<td>Secondary to PH/MVD</td>
<td>What Type of Intervention?</td>
<td></td>
</tr>
<tr>
<td>Secondary to PH without MVD</td>
<td>OMT vs Intervention</td>
<td></td>
</tr>
</tbody>
</table>

**Presenter:** Rebecca T. Hahn, MD, FACC  
**Discussants:** David H. Adams, MD, FACC; Robert O. Bonow, MD, MACC; Ismail El-Hamamsy, MD, PhD; Martin B. Leon, MD, FACC; Samin K. Sharma, MBBS, FACC; and Gregg W. Stone, MD, FACC

**4:35 – 5 p.m.**  
Hypertrophic Cardiomyopathy: Five Challenging Questions — Genetic/Acquired, Mavacamten, Myectomy, Apical and Sudden Death  
Steve R. Ommen, MD, FACC

**5 p.m.**  
Adjournment

---

**Sunday, Dec. 10**

**Year in Review: Ten Highlights of Progress in 2023**

**Session IX: Novelties on Pharmacology, Clinical and Epidemiological CV Science**  
Chair: Valentin Fuster, MD, PhD, MACC

- **8 – 8:20 a.m.**  
  Disrupting the Care of Cardiovascular Disease With Single-course Gene Editing Medicines  
  Amit V. Khera, MD, MSc

- **8:20 – 8:40 a.m.**  
  Gut Microbiome and Heart Disease: Understanding and Future Management  
  W. H. Wilson Tang, MD, FACC

- **8:40 – 9 a.m.**  
  Inflammasome and Atherosclerosis  
  Alan Tall, MD

- **9 – 9:20 a.m.**  
  Interleukin 1 Inhibitors: Idiopathic Recurrent Pericarditis  
  Allan L. Klein, MD, CM, FACC

*Agenda as of Oct. 20, 2023. Subject to change.*
<table>
<thead>
<tr>
<th>Time</th>
<th>Session Title</th>
<th>Speaker(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>9:20 – 9:40 a.m.</td>
<td>Immune Checkpoint Therapies - Myocardial and Coronary Side Effects</td>
<td>Bonnie Ky, MD, MSCE, FACC</td>
</tr>
<tr>
<td>9:40 – 10 a.m.</td>
<td>Detection and Management of Vulnerable Plaque: Intravascular Imaging</td>
<td>Akiko Maehara, MD</td>
</tr>
<tr>
<td>10 – 10:20 a.m.</td>
<td>Triglycerides and HDL- Cholesterol: What Are the Questions?</td>
<td>Robert S. Rosenson, MD, FACC</td>
</tr>
<tr>
<td>10:20 – 10:40 a.m.</td>
<td>Transcatheter Intervention in CHD: Septal Defects and Valve Dysfunction</td>
<td>TBD</td>
</tr>
<tr>
<td>10:40 – 11 a.m.</td>
<td>Early Detection of Atherothrombotic Disease and Monitoring: EDM Program</td>
<td>Borja Ibanez, MD, PhD</td>
</tr>
<tr>
<td>11 – 11:30 a.m.</td>
<td>Global Trends in Cardiovascular Diseases and Mortality Rates</td>
<td>Valentin Fuster, MD, PhD, MACC</td>
</tr>
<tr>
<td>11:30 a.m.</td>
<td>Adjourn</td>
<td></td>
</tr>
</tbody>
</table>

*Agenda as of Oct. 20, 2023. Subject to change.*